Pneumocystis in Patients Over 75 Year

NCT07004127 | Completed

• 1 other identifier: IRB_22.01.05
• Study Type: observational
• Target: 162
• Locations: 1 country
• Sites: 1

Brief Summary

Pneumocystis pneumonia is an infectious disease caused by Pneumocystis jirovecii that affects the lung parenchyma preferentially. Historically described in an immunocompromised population through HIV. Worldwide, the profile of patients affected by this pathology is changing due to two main factors:

• The sustainable stabilization of HIV patients.
• The emergence of new risk factors of immunosuppression. The geriatric population is particularly affected by these risk factors, increasing the incidence of pneumocystis in this population, which does not have HIV (solid cancer, hemopathy, immunosuppressive treatments, etc.). There is currently no work specifically studying pneumocystis in this age group. The main objective of this study is to describe the clinical, biological and therapeutic data of a cohort of geriatric patients with pneumocystis, not carrying HIV, from January 1, 2010 to December 31, 2021, in all the centers surveyed.

Conditions

Pneumocystis

Outcome Measures

Primary Outcomes (3)

• Clinical data

  description of clinical data

  From DAY 0 to end of treatment

• Therapeutic data

  description of treatment provide to treat pneumocystosis

  From DAY 0 to end of treatment

• Biological data

  Analysis of biological data realized during follow up

  From DAY 0 to end of treatment

Study Arms (1)

geriatric patient with pneumocystis

geriatric patient with pneumocystis, not HIV positive,

Eligibility Criteria

• Age: 75 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

geriatric patient with pneumocystis, not HIV positive, over 75 years old

You may qualify if:

• Patient \> or equal to 75 years of age
• Microbiological diagnosis:
• Direct examination with standard stain, finding trophozoite and/or P.jirovecii cyst (BAL or induced sputum) And/or
• Direct examination with immunofluorescence, finding trophozoite and/or P.jirovecii cyst (BAL or induced sputum)
• And/or
• Positive PCR (BAL, sputum, nasopharyngeal swab or blood) and CT \< 35
• Absence of HIV infection
• Hospitalization in French hospitals between 2010 and 2021
• \. Opposition of the patient to participate to the study

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

Study Sites (1)

CHU de NIMES

Nîmes, 30029, France

Location

MeSH Terms

Conditions

Pneumonia, Pneumocystis

Condition Hierarchy (Ancestors)

Lung Diseases, Fungal; Mycoses; Bacterial Infections and Mycoses; Infections; Pneumocystis Infections; Respiratory Tract Infections; Pneumonia; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Adrien BARRAUD

  CHU NIMES

  PRINCIPAL INVESTIGATOR

• Albert SOTTO, Md, PhD

  CHU NIMES

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 31, 2022
• First Posted: June 4, 2025
• Study Start: January 1, 2010
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2023
• Last Updated: June 4, 2025

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)